Author

J. Jain

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Bioengineering· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Delpal· 2 shared A. Evagelidis· 2 shared B. Coutard· 2 shared C. Mapa· 2 shared D. DeRyckere· 2 shared D. Huynh· 2 shared D. K. Graham· 2 shared D. Susan-Resiga· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

A. Delpal

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML

J. M. Kelvin, J. Jain, A. Thapa, M. Qui, L. A. Birnbaum, S. G. Moore, H. Zecca, R. J. Summers, E. Costanza, B. Uricoli, X. Wang, N. T. Jui, H. Fu, Y. Du, D. DeRyckere, , E. C. Dreaden

The paper develops a nanoscale combination drug formulation targeting MERTK, FLT3, and BCL-2 to treat AML, showing improved synergistic responses in vitro and in patient samples.

bioRxiv · Mar 13, 2023 · PreprintBioengineering

Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic Leukemia

J. M. Kelvin, D. Y. Zhang, E. K. Williams, S. G. Moore, L. A. Birnbaum, H. Zecca, X. Wang, J. Jain, M. Qui, N. T. Jui, H. Fu, Y. Du, M. L. Kemp, W. A. Lam, D. DeRyckere, , E. C. Dreaden

The paper identifies synergistic drug combinations for T-ALL using high-throughput screens and develops lipid nanoparticle formulations that maintain drug synergy and improve anti-leukemic activity.

bioRxiv · Sep 21, 2022 · PreprintBioengineering

Implications of Spike-glycoprotein processing at S1/S2 by Furin, at S2' by Furin and/or TMPRSS2 and shedding of ACE2: cell-to-cell fusion, cell entry and infectivity of SARS-CoV-2

R. Essalmani, J. Jain, D. Susan-Resiga, U. Andreo, A. Evagelidis, M. Derbali, D. Huynh, F. Dallaire, M. Laporte, A. Delpal, P. Sutto-Ortiz, B. Coutard, C. Mapa, K. Wilcoxen, E. Decroly, , N. G. Seidah

The paper discusses the implications of spike-glycoprotein processing by Furin and TMPRSS2 on SARS-CoV-2 infectivity and cell entry, but the manuscript has been withdrawn.

bioRxiv · Jul 2, 2021 · PreprintBiochemistry

SARS-CoV-2 spike-glycoprotein processing at S1/S2 and S2' and shedding of the ACE2 viral receptor: roles of Furin and TMPRSS2 and implications for viral infectivity and cell-to-cell fusion

R. Essalmani, J. Jain, D. Susan-Resiga, U. Andreo, A. Evagelidis, R. M. Derbali, D. Huynh, F. Dallaire, M. Laporte, A. Delpal, P. Sutto-Ortiz, B. Coutard, C. Mapa, K. Wilcoxen, E. Decroly, , N. G. Seidah

This study investigates the roles of Furin and TMPRSS2 in SARS-CoV-2 spike protein processing and viral entry, showing their synergistic effects and suggesting combined inhibitors as antivirals.

bioRxiv · Dec 18, 2020 · PreprintBiochemistry